<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101149</url>
  </required_header>
  <id_info>
    <org_study_id>262231</org_study_id>
    <nct_id>NCT04101149</nct_id>
  </id_info>
  <brief_title>Genetic Causes of Familial Hypercholesterolemia</brief_title>
  <official_title>Genetiska Orsaker Till familjär Hyperkolesterolemi- Mekanism, Prognos Och Individanpassad Behandling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Örebro County</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Örebro County</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial hypercholesterolemia (FH) is a common disease. The genetic background to FH is not&#xD;
      yet fully understood. In the present prospective cohort study we aim to study the association&#xD;
      between different clinical characteristics, gene mutations and prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective observational cohort study of patients with high clinical suspicion of&#xD;
      familial hypercholesterolemia (FH) we aim to study the association between different clinical&#xD;
      characteristics, gene mutations and prognosis.&#xD;
&#xD;
      The included patients will undergo physical examination and extended blood sampling. DNA will&#xD;
      be extracted and used for both whole genome sequencing and investigation of both known- ,&#xD;
      unknown- and suspected mutations associated with FH.&#xD;
&#xD;
      The patients will be followed in for 15 years in the Swedish patients registry and the&#xD;
      Swedish cause of death registry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 2045</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of mutations.</measure>
    <time_frame>2 years</time_frame>
    <description>The prevalence of known and newly discovered mutations associated with FH in the study population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognosis, composite endpoint.</measure>
    <time_frame>10 years</time_frame>
    <description>Time to death (cardiovascular and total), hospitalization due to acute myocardial infarction, unstable angina, heart failure or stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognosis, individual endpoint.</measure>
    <time_frame>10 years</time_frame>
    <description>Time to the individual endpoints: death (cardiovascular and total), hospitalization due to acute myocardial infarction, unstable angina, heart failure, stroke.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients with high clinical suspicion of familial hypercholesterolemia. No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for investigation of lipids, electrolytes, markers of inflammation and&#xD;
      myocardial injury. Blood samples for extraction of DNA for genetic analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with suspected FH referred to the cardiac clinic at Orebro University hospital&#xD;
        and their first grade relatives.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 8 years or older.&#xD;
&#xD;
          2. Clinical suspicion of FH&#xD;
&#xD;
          3. Dutch Lipid Clinic Network Score of at least four or a first grade relative with a&#xD;
             genetic deviation that may be associated with FH.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Age below 8 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna M Nordenskjöld, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örebro University, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna M Nordenskjöld, MD, PhD</last_name>
    <phone>+46 19 6021000</phone>
    <email>anna.nordenskjold@regionorebrolan.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Green, PhD</last_name>
    <phone>+46 19 6021000</phone>
    <email>anna.green@regionorebrolan.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Örebro University hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna M Nordenskjöld, MD, PhD</last_name>
      <phone>+46 19 6021000</phone>
      <email>anna.nordenskjold@regionorebrolan.se</email>
    </contact>
    <contact_backup>
      <last_name>Anna Green, PhD</last_name>
      <phone>+46 19 6021000</phone>
      <email>anna.green@regionorebrolan.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

